January 2024 Report

Happy New Year! What a great start to the year with a whopping +0.02% gain! This can be attributed to the recent pull back in Apple, which makes up ~ 40% of the portfolio. It’s a high concentration in one position and I’m actually considering adding to it. I view the Vision Pro as an iPhone moment and a new inflection point for Apple. I won’t be purchasing the first gen Vision Pro, but a maybe a second or third gen model. I can just imagine making trades with just a blink of an eye…  

No arb plays at the moment. With a wacko FTC chair, they will take an opportunity to block everything in sight. It’s no longer like the good old days when you can pretty much guarantee a HSR approval for any bolt on pharma acquisition. Most acquisitions will still go through, but you have to sweat it out a bit as they like to drag things out with a Second Request.

We need some nice IPOs this year…

 

2024 Performance = + 0.02% with the running monthly returns as follows:

January + 0.02%